NYSEAMERICAN:PFNX Pfenex (PFNX) Stock Price, News & Analysis $12.75 0.00 (0.00%) As of 10/1/2020 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Pfenex Stock (NYSEAMERICAN:PFNX) Get Pfenex alerts:Sign Up Key Stats Today's Range$12.75▼$12.7550-Day Range$12.75▼$12.7552-Week Range$5.26▼$14.00VolumeN/AAverage Volume503,865 shsMarket Capitalization$437.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Pfenex, Inc. is a San Diego–based contract development and manufacturing organization (CDMO) focused on recombinant protein expression. Publicly traded on the NYSE American under the ticker PFNX, the company applies its proprietary Pfenex Expression Technology to the development and production of proteins for biopharmaceutical applications. Its services span process development, analytical method development, cGMP manufacturing and sterile formulation and fill–finish operations. The Pfenex Expression Technology platform utilizes a modified Pseudomonas fluorescens host system engineered for high-yield, cost-effective production of therapeutic proteins, biosimilar candidates and vaccine antigens. By combining rapid microbial expression with streamlined downstream processing, Pfenex supports preclinical, clinical and commercial campaigns, helping partners reduce scale-up risk and accelerate time to market. Founded in 2002 and completing its initial public offering in 2014, Pfenex has forged collaborations and supply agreements with pharmaceutical and biotechnology companies across North America, Europe and the Asia-Pacific region. The company’s global footprint and modular manufacturing facilities enable it to address diverse project requirements, from early-stage development through commercial launch. Under the leadership of President and Chief Executive Officer Jerel Davis, Pfenex continues to invest in facility expansions and technology enhancements. As the biopharmaceutical industry increasingly outsources protein development and manufacturing, Pfenex aims to leverage its platform and flexible operations to meet the evolving needs of its global client base.AI Generated. May Contain Errors. Read More Receive PFNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pfenex and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PFNX Stock News HeadlinesNKY Medical Holdings Ltd Class A 300109January 31, 2024 | morningstar.comMLigand Pharmaceuticals: Struggling Along (NASDAQ:LGND) - Seeking AlphaSeptember 25, 2022 | seekingalpha.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.May 14 at 1:00 AM | Paradigm Press (Ad)Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update - Business WireAugust 15, 2022 | businesswire.comLigand Reports Second Quarter 2022 Financial Results - Business WireAugust 9, 2022 | businesswire.com2022-08-08 | NDAQ:LGND | Press Release | Ligand Pharmaceuticals Incorporated - StockhouseAugust 8, 2022 | stockhouse.comOsteoporosis Therapeutics Market to Top US$ 14 Bn Valuation by 2026: Fact.MR Analysis - Yahoo FinanceMay 17, 2022 | finance.yahoo.comLigand Reports First Quarter 2022 Financial Results - StreetInsider.comMay 5, 2022 | streetinsider.comSee More Headlines PFNX Stock Analysis - Frequently Asked Questions How have PFNX shares performed this year? Pfenex's stock was trading at $12.75 at the start of the year. Since then, PFNX stock has increased by 0.0% and is now trading at $12.75. How were Pfenex's earnings last quarter? Pfenex Inc. (NYSEAMERICAN:PFNX) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.07. The biotechnology company earned $0.68 million during the quarter, compared to analyst estimates of $3.75 million. How do I buy shares of Pfenex? Shares of PFNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pfenex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pfenex investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Bristol Myers Squibb (BMY), Gilead Sciences (GILD) and Ocular Therapeutix (OCUL). Company Calendar Last Earnings5/07/2020Today5/14/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:PFNX Previous SymbolNYSEMKT:PFNX CIKN/A Webwww.pfenex.com Phone+1-858-3524400FaxN/AEmployees71Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares34,297,000Free FloatN/AMarket Cap$437.29 million OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSEAMERICAN:PFNX) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely, LLC | SponsoredMusk's acquisition pattern points to ONE stockMusk needed solar - he acquired SolarCity. Needed data - he bought Twitter. The pattern is clear: when a suppl...Behind the Markets | SponsoredTrump Just Named His Secret AI Project. It's Called "Golden Dawn."Behind a hidden government lab in Tennessee, 40,000 scientists are reportedly finishing work on an AI system d...InvestorPlace | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfenex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pfenex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.